Clinical Trial Update: Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating anlotinib in combination with docetaxel for EGFR wild-type advanced non-small-cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Hunan Cancer Hospital | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN